Patent US3985618A successfully refreshed from Google Patents.
US3985618A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for detection of thrombosis and prethrombosis
Assignee: Individual
•
Filing: 1975-10-24
•
Granted: 1976-10-12
•
Expires: 1995-10-24
Abstract
Abstract The combination of two tests, a procoagulant assay (PA) and a heparin-procoagulant assay (H-PA) makes it possible to determine the status of a patient with respect to thrombosis and whether a prethrombotic condition exists. The results of the tests can be used to determine whether and what type of treatment is necessary.
Inventors
- 👤 Irving Innerfield
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 22:04
CPC Classifications
C; C12; C12Q; C12Q1/00; C12Q1/56; G; G01; G01N; G01N2333/00; G01N2333/90; G01N2333/914; G01N2333/948; G01N2333/974; G01N2400/00; G01N2400/10; G01N2400/38; G01N2400/40
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
165 words
A method of measuring serum coagulability in a patient comprising the steps of adding heparin in different amounts to aliquots of serum from a patient, adding each of the resultant heparin-serum solutions to a separate tube containing thrombin solution, reacting a portion of each of the resultant thrombin-heparin-serum solutions with normal plasma solution to determine whether clotting occurs, and in the event clotting occurs, determining the clotting time, all steps being carried out under standardized conditions at at least one selected temperature, thereby making it possible to compare the measured clotting times with clotting time ranges obtained under standardized conditions with serum from healthy unmedicated individuals and from known thrombotic individuals, and to establish whether the measured clotting times fall within a first normal range corresponding to normal, unmedicated individuals, a second low range corresponding to thrombotic individuals, or third and fourth ranges intermediate said normal and low ranges and corresponding to individuals of increasing coagulability, a low clotting time correlating with high serum coagulability.
Claim 2
Independent Claim
165 words
A method of measuring serum coagulability in a patient comprising the steps of adding heparin in different amounts to aliquots of serum from a patient, adding each of the resultant heparin-serum solutions to a separate tube containing thrombin solution, reacting a portion of each of the resultant thrombin-heparin-serum solutions with normal plasma solution to determine whether clotting occurs, and in the event clotting occurs, determining the clotting time, all steps being carried out under standardized conditions at at least one selected temperature, thereby making it possible to compare the measured clotting times with clotting time ranges obtained under standardized conditions with serum from healthy unmedicated individuals and from known thrombotic individuals, and to establish whether the measured clotting times fall within a first normal range corresponding to normal, unmedicated individuals, a second low range corresponding to thrombotic individuals, or third and fourth ranges intermediate said normal and low ranges and corresponding to individuals of increasing coagulability, a low clotting time correlating with high serum coagulability.
Claim 3
Dependent Claim
79 words
The method of measuring serum coagulability in a patient as defined in claim 1, further comprising the steps of reconstituting solid plasma with distilled water to prepare normal plasma, reconstituting solid thrombin with isotonic saline to form a thrombin solution, and standardizing said thrombin solution by diluting same with isotonic saline until 0.1 ml of diluted thrombin solution clots 0.2 ml of normal plasma in 10.5 - 11 seconds, both the thrombin and the plasma solutions being at 37°C.
Claim 4
Dependent Claim
51 words
The method of measuring serum coagulability in a patient as defined in claim 2 wherein said aliquots are four in number and are each 0.1 ml in volume, the quantities of heparin added to said four aliquots being 0.1 ml of solution containing respectively, 1.0, 0.7, 0.6 and 0.5 heparin units.
Claim 5
Dependent Claim
77 words
The method of measuring serum coagulability in a patient as defined in claim 3, further comprising the steps of adding each of said heparin-serum solutions to 0.9 ml of standardized thrombin solution, incubating said heparin-serum-thrombin solutions at 37°C for 2 minutes, adding 0.1 ml of each of said incubated solutions to a separate tube each containing 0.2 ml of normal plasma equilibrated at 37°C, and noting the clotting times for the contents of each of said tubes.
Claim 6
Dependent Claim
24 words
The method of measuring serum coagulability in a patient as defined in claim 1, wherein said clotting times are noted by an automatic device.
Claim 7
Dependent Claim
125 words
The method of measuring serum coagulability in a patient as defined in claim 1, further comprising the steps of mixing a further portion of serum from a patient with a quantity of a second thrombin solution, mixing a portion of said thrombin-serum mixture with a further portion of plasma, all steps being carried out under standardized conditions, and noting the clotting time, thereby making it possible to compare the measured clotting time of said mixed portion of second thrombin solution, serum and plasma with the clotting time range obtained under standardized conditions with serum from healthy, unmedicated individuals and with serum from patients suffering from known pathologies, a clotting time below the range characteristic of healthy, unmedicated individuals indicating a decrease in fibrinogen degradation products.
Claim 8
Dependent Claim
72 words
The method of measuring serum coagulability in a patient as defined in claim 6, further, comprising the steps of reconstituting solid plasma with distilled water to form normal plasma, reconstituting solid thrombin with isotonic saline to form a second thrombin solution, and standardizing said second thrombin solution by diluting same with isotonic saline until 0.1 ml of diluted second thrombin solution clots 0.2 ml of normal plasma in 15 - 16 seconds.
Claim 9
Dependent Claim
112 words
The method of measuring serum coagulability in a patient as defined in claim 7, wherein said quantity of second thrombin solution is 0.9 ml, said further portion of serum is 0.1 ml, said further portion of plasma is 0.2 ml, said further portion of plasma having been equilibrated at 37°C, the quantity of thrombin-serum mixture mixed with said further portion of plasma being 0.1 ml and further comprising the steps of incubating said mixture of said second thrombin solution and said further portion of serum at 37°C for 3 minutes immediately prior to adding 0.1 ml thereof to said further portion of plasma, and observing the clotting time of the plasma-thrombin-serum mixture.
Claim 10
Dependent Claim
37 words
The method of measuring serum coagulability in a patient as defined in claim 8, wherein the clotting times of said mixed second thrombin solution and further portions of serum and plasma are noted by an automatic device.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1979-10-12 | 1980-04-12 | 1980-10-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1983-10-12 | 1984-04-12 | 1984-10-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1987-10-12 | 1988-04-12 | 1988-10-12 | $7700.00 | Window Closed / Lapsed |